Tofa for RA by the grp of Dr. Atul Deodhar: >Tofa(56%) vs. pbo(29.4%)-significant improvement in ASAS20 at wk 16 >Primary & secondary endpts met >No new safety signals reported @Rheumnow #ACR20 https://t.co/G9U5cCQU7K

Poll results are in! 76% of you take into account the location of bone marrow edema in the SI joint of patients with inflammatory back pain in trying to determine if a patient has SpA! #ACR20 @RheumNow https://t.co/gwySNvfSH5

• https://twitter.com/meralelramahimd/status/1325809021413187586

📌 #ACR20 Checkpoint Inhibitors: Past, Present and Future 👉close surveillance ➡️ early detection of iRAEs➡️ early treatment➡️ reversibility or ⬇️severity #ACRAmbassador https://t.co/AM2mfYmAtI

And we're off! #ACR20 year in review ⭐️@philseo's #Vasculitis lecture⭐️ Take home lessons/ remaining questions from GiACTA ⬇️ #ACRambassador https://t.co/7C9QxbUeNH

📌More #Vasculitis pearls from #ACR20 Year in Review #PEXIVAS in a nutshell ⬇️ #ACRambassador https://t.co/PnoP7QIiYs

Pfizer vaccine data potentially shows >90% effectiveness via ⁦@nytimes⁩ https://t.co/jwVkmbMaTL

• https://www.nytimes.com/2020/11/09/health/covid-vaccine-pfizer.html?referringSo…

from #ACR20 Dr. Abbey Abelson. There was reduction in hip fractures in the US until there was drop in reimbursement for DEXA/Bone Density. @ACRheum has been advocating on Capitol Hill to restore reimbursement. Bad policy harms, but good policy can save lives. #ACRambassador https://t.co/ARo762Vozp

Thank you Prof Laure Gossec for discussing recent data in Psoriatic Arthritis #ACR20 #ACRambassador https://t.co/f0o8m5K0d2 https://t.co/Wm0sQDUeY1

• ACR Convergence 2020

Some behind the scenes action at #ACR20 #ACRKnowledgeBowl!! More to come tomorrow at 1pm EST with finals! https://t.co/3yLgqqC0Yy

ARCH study -- n~4100 Romo vs Alendronate x 12 mo Alendronate 12-24 mo RRR 38% https://t.co/d0G7x4TqUT

Hypophosphatasia - CPPD/chondrocal, enthesop'y, DISH, exostoses - DDx of Low ALP: milk-alkali, Vit D intoxic'n, Wilson dz, via C def, celiac dz, adyn renal osteodystrophy, Cushing dz, hypothyroid, major sx, MM Rx - asfotase alpha- bone targeted replac't Rx #ACR20 #ACRambassador https://t.co/FJ1355MdKG

#ACR20 Abstracts on #ILD Rituximab in ILD (all observational) #1053 ➡️ 47 with CTD-ILD: overall improvement or stability at 36m #1051 ➡️ 50 with IPAF: >70% stable or improved at 12m #1047 ➡️ 47 patients CTD-ILD or IPAF: good experience with MMF and RTX #ACRambassador https://t.co/klfVwIH5b6

Over 20,000 tweets and 65 Million+ Impressions Check out the details at https://t.co/Z6X1EeOsnr https://t.co/OtqWZCiu6h

• #ACR20 Healthcare Social Media Analytics